FY2026 Earnings Estimate for Sernova Issued By HC Wainwright

Sernova Corp. (TSE:SVA) – Equities researchers at HC Wainwright issued their FY2026 earnings estimates for shares of Sernova in a research note issued to investors on Tuesday, September 8th. HC Wainwright analyst J. Pantginis anticipates that the company will post earnings of ($0.03) per share for the year. The consensus estimate for Sernova’s current full-year earnings is ($0.08) per share. HC Wainwright also issued estimates for Sernova’s FY2027 earnings at ($0.03) EPS and FY2028 earnings at ($0.05) EPS.

Sernova Price Performance

SVA stock opened at C$0.14 on Friday. The company has a current ratio of 0.14, a quick ratio of 18.11 and a debt-to-equity ratio of -25.45. The company’s 50-day moving average price is C$0.12 and its 200 day moving average price is C$0.14. Sernova has a 52 week low of C$0.10 and a 52 week high of C$0.20. The company has a market cap of C$52.87 million, a P/E ratio of -3.50 and a beta of -0.43.

Sernova (TSE:SVA) last posted its quarterly earnings results on Thursday, September 10th. The company reported C($0.01) earnings per share for the quarter.

About Sernova

Sernova Biotherapeutics is a clinical-stage company developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem-cell derived islet-like clusters in collaboration with Evotec to create bio-hybrid organs to treat T1D. A bio-hybrid organ is comprised of non-biomaterials, such as the Cell Pouch, integrated with living tissues to restore or enhance the function of a compromised organ. This innovative approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on T1D and thyroid disorders.